Adrian V. Hernandez

4

Articles

0

Comments
Though drug recalls are relatively uncommon in the U.S., reduced inspections increase the likelihood of manufacturing errors that slip through the cracks. AP Photo/Rafiq Maqbool

The FDA’s weak drug manufacturing oversight is a potentially deadly problem

Adrian V. Hernandez, University of Connecticut and C. Michael White, University of Connecticut

COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
Pharmaceutical companies recalled metformin, a Type 2 diabetes drug, after finding high levels of NDMA impurities. Scott Olson via Getty Images

Zantac unlikely to turn into cancer‑causing chemical in the body, but concerns remain about how drugs age on the shelf

C. Michael White, University of Connecticut and Adrian V. Hernandez, University of Connecticut

The FDA recalled commonly used heartburn and ulcer medication ranitidine in April 2020. But new research suggests less reason for alarm.

Contact Adrian for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision